A Multicenter Real World Study of Kanglaite for Cancer Cachexia

Zhejiang Kanglaite Pharmaceutical

Status: Unknown

Conditions: Cancer Cachexia

Treatments: Drug: Kanglaite Injection/Capsules

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT03631459

KLT-2018

Details and patient eligibility

About

A prospective, multi-center real-world study of the effectiveness and safety of Kanglaita Injection/Capsule in Chinese patients with cancer cachexia

Full description

This is a large national-based prospective, multi-center real-world observational study. Cancer cachexia patients scheduled for sequential treatment with Kanglaite injection and capsule between August 2018 and March 2020 at 640 participating hospitals will be recruited to evaluate the effectiveness and safety of Kanglaite.

Enrollment: 100,000 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients with pathological or cytological diagnosis of lung, liver, pancreatic or stomach cancer; Patients scheduled to receive Kanglaite injection for 7 or more days, followed by Kanglaite capsule for 14 or more days; Patients willing to participate in this study and provide written informed consent.

Exclusion criteria

None

Trial design

100,000 participants in 1 patient group

Kanglaite Injection/Capsules

Description:

Kanglaite injection 200ml, iv. gtt qd×7d or more, followed by Kanglaite capsule 0.45g×6 tablets qid po×14d as one cycle for at least 4 cycles

Treatment:

Drug: Kanglaite Injection/Capsules